SFX by Ex Libris Inc.

Title:	A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth
Source:	Nature Medicine [1078-8956] Niethammer, Andreas yr:2002

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Koide, Y. "Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium." The journal of immunology (1998): 5594-5599.
description	2.	Ramage JM, JM. "The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2." Cancer immunology, immunotherapy 55.8 (2006): 1004-1010.
description	3.	Mufti, Areej H H. "Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use." Diagnostic microbiology and infectious disease 53.3: 233-238.
description	4.	Cho, H. "Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1." Vaccine 25.47 (2007): 8049-8057.
description	5.	Calabrese, L. "The yin and yang of tumor necrosis factor inhibitors." Cleveland Clinic journal of medicine 73.3 (2006): 251-256.
description	6.	Mohan, Aparna K K. "Infectious complications of biologic treatments of rheumatoid arthritis." Current opinion in rheumatology 15.3 (2003): 179-184.
description	7.	Stübgen, Joerg-Patrick P. "Tumor necrosis factor-alpha antagonists and neuropathy." Muscle & nerve 37.3 (2008): 281-92.
description	8.	Plum, S. "Administration of FGF-2 peptide vaccine leads to abrogation of angiogenesis and tumor development." European journal of cancer 38 (2002).
description	9.	Hu, Chun X. "Secretory expression of K88 (F4) fimbrial adhesin FaeG by recombinant Lactococcus lactis for oral vaccination and its protective immune response in mice." Biotechnology letters 31.8 (2009): 1311-997.
description	10.	Margulies, D H H. "TCR avidity: it's not how strong you make it, it's how you make it strong." Nature immunology 2.8 (2001): 669-70.
description	11.	Carson-Walter, E. "Cell surface tumor endothelial markers are conserved in mice and humans." Cancer research 61.18 (2001): 6649-6655.
description	12.	Grivennikov, S. "Distinct and nonredundant in vivo functions of TNF produced by T cells and macrophages/neutrophils: Protective and deleterious effects." Immunity 22.1 (2005): 93-104.
description	13.	Seder, R A A. "DNA vaccines: immunology, application, and optimization*." Annual review of immunology 18.1 (2000): 927-74.
description	14.	Keystone, G. "Safety of biologic therapies--an update." The Journal of rheumatology. Supplement 74 (2005): 8-12.
description	15.	Saliu, Oluwabunmi Y Y. "Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity." The journal of infectious diseases 194.4 (2006): 486-492.
description	16.	Criscione, Lisa G G. "Tumor necrosis factor-(alpha) antagonists for the treatment of rheumatic diseases." Current opinion in rheumatology 14.3 (2002): 204-211.
description	17.	Ault, Kevin A. "Long-term efficacy of human papillomavirus vaccination." Gynecologic Oncology 107.2s (2007): 27-30.
description	18.	Brezinschek, Kerstin I. "Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes." Wiener medizinische Wochenschrift 156.1-2 (2005): 61-67.
description	19.	Stanley, M. "Prevention strategies against the human papillomavirus: The effectiveness of vaccination." Gynecologic Oncology 107.2 (2007): -23.
description	20.	Taboada, Maria T. "HPV vaccine Beyond the hype." Consumer reports 72.10 (2007): 47-47.